Novavax and Serum Institute of India Announce World Health Organization Grants Emergency Use Listing for NVX-CoV2373 COVID-19 Vaccine
Dec 20, 2021
First EUL granted by WHO for a protein-based COVID-19 vaccine EUL vaccine manufactured and marketed by SII as COVOVAX™ WHO EUL for Nuvaxovid™ currently under assessment; will be completed following European Medicines Agency (EMA) review GAITHERSBURG, Md. and PUNE, India, Dec. 20, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India